R Squared’s Nektar Therapeutics NKTR Stock Holding History

R Squared’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-248	Closed	-$3.46K	–	1066
2024 Q4	$3.46K	Buy	+248	New	+$4.37K	﹤0.01%	1387

Other funds holding NKTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

R Squared's NKTR Position: Q1 2025 in Review

R Squared sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 248 shares — an estimated $3.46K sold.

R Squared first reported a position in NKTR in Q4 2024 and held it in 1 quarter. The position peaked at $3.46K in Q4 2024. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

R Squared reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 248 Nektar Therapeutics shares in Q1 2025, an estimated $3.46K.
R Squared first reported a position in Nektar Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Nektar Therapeutics position peaked at $3.46K in Q4 2024.
154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.